ChemoMetec Investor Relations Material

ChemoMetec is a Danish biotech company that specializes in the development and production of cell counting and analysis systems for use in the life sciences industry. The company was founded in 1997 and has since become a leading provider of advanced cell analysis solutions to customers around the world. Some of ChemoMetec’s competitors include Thermo Fisher, MERCK, and GE Healthcare. 

ChemoMetec's business model is based on providing high-quality, reliable, and easy-to-use cell analysis systems that enable researchers to obtain accurate and reproducible results. The company's products include the NucleoCounter and NC-202 instruments, which are used by researchers in a variety of applications, including drug discovery, cancer research, and stem cell research.

ChemoMetec generates revenue primarily through the sale of its cell analysis systems, as well as through ongoing customer support and service contracts. The company's revenue is also generated through its partnerships with other biotech and life sciences companies, as well as through collaborations with academic research institutions.

ChemoMetec's cell analysis systems have gained a reputation for their accuracy and reliability, with a high degree of precision in cell counting and analysis. The company has also been recognized for its user-friendly approach to design and software, making their systems easy to operate and accessible to a wide range of researchers.